Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Myelodysplastic Syndromes 19Lymphoma, Non-Hodgkin 17Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Graft vs Host Disease 13Lymphoma, Mantle-Cell 12Leukemia 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Sarcoma 10Lymphoma 10Lymphoma, Follicular 9Lymphoma, B-Cell, Marginal Zone 9Burkitt Lymphoma 9Myeloproliferative Disorders 8Waldenstrom Macroglobulinemia 7Tuberous Sclerosis 7Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Hematologic Neoplasms 7Congenital Abnormalities 7Primary Myelofibrosis 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myeloid, Accelerated Phase 6Breast Neoplasms 6Osteosarcoma 5

Interventions

Paclitaxel 6Doxorubicin 6Gemcitabine 4Bevacizumab 4pembrolizumab 3pazopanib 3durvalumab 3Sorafenib 3Docetaxel 3trebananib 2spartalizumab 2cemiplimab 2brostallicin 2Propranolol 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Imatinib Mesylate 2Ifosfamide 2Carboplatin 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trastuzumab duocarmazine 1temsirolimus 1talimogene laherparepvec 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hemangiosarcoma × Sirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡